AnaptysBio, Inc. (NASDAQ:ANAB) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of AnaptysBio, Inc. (NASDAQ:ANAB) have earned a consensus rating of “Moderate Buy” from the thirteen ratings firms that are presently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have assigned a buy rating to the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $81.8182.

A number of equities analysts recently commented on ANAB shares. Wall Street Zen downgraded AnaptysBio from a “strong-buy” rating to a “hold” rating in a report on Saturday, May 16th. Weiss Ratings downgraded AnaptysBio from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, May 13th. Zacks Research downgraded AnaptysBio from a “strong-buy” rating to a “hold” rating in a report on Tuesday, June 2nd. Truist Financial raised AnaptysBio to a “hold” rating in a research report on Wednesday, March 25th. Finally, Piper Sandler decreased their target price on AnaptysBio from $95.00 to $93.00 and set an “overweight” rating for the company in a research report on Monday, May 4th.

Insider Buying and Selling

In other AnaptysBio news, Director John P. Schmid sold 20,645 shares of the company’s stock in a transaction that occurred on Monday, March 30th. The stock was sold at an average price of $56.11, for a total transaction of $1,158,390.95. Following the completion of the sale, the director owned 31,622 shares of the company’s stock, valued at $1,774,310.42. This represents a 39.50% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Daniel Faga sold 17,679 shares of the company’s stock in a transaction that occurred on Friday, March 27th. The stock was sold at an average price of $61.61, for a total value of $1,089,203.19. Following the sale, the chief executive officer directly owned 495,965 shares of the company’s stock, valued at $30,556,403.65. The trade was a 3.44% decrease in their position. The SEC filing for this sale provides additional information. 33.50% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On AnaptysBio

A number of large investors have recently added to or reduced their stakes in ANAB. Granahan Investment Management LLC boosted its position in shares of AnaptysBio by 12.2% in the third quarter. Granahan Investment Management LLC now owns 147,773 shares of the biotechnology company’s stock valued at $4,525,000 after acquiring an additional 16,118 shares during the period. Vanguard Group Inc. boosted its position in shares of AnaptysBio by 4.5% in the fourth quarter. Vanguard Group Inc. now owns 1,544,037 shares of the biotechnology company’s stock valued at $74,855,000 after acquiring an additional 67,048 shares during the period. Skandinaviska Enskilda Banken AB publ boosted its position in shares of AnaptysBio by 333.1% in the third quarter. Skandinaviska Enskilda Banken AB publ now owns 145,191 shares of the biotechnology company’s stock valued at $4,446,000 after acquiring an additional 111,668 shares during the period. BNP Paribas Financial Markets boosted its position in shares of AnaptysBio by 56.0% in the fourth quarter. BNP Paribas Financial Markets now owns 164,823 shares of the biotechnology company’s stock valued at $7,991,000 after acquiring an additional 59,160 shares during the period. Finally, Tema Etfs LLC boosted its position in shares of AnaptysBio by 105.6% in the fourth quarter. Tema Etfs LLC now owns 22,560 shares of the biotechnology company’s stock valued at $1,094,000 after acquiring an additional 11,585 shares during the period.

AnaptysBio Stock Performance

NASDAQ:ANAB opened at $56.07 on Monday. The stock’s 50 day moving average price is $60.34 and its 200 day moving average price is $54.50. AnaptysBio has a 52 week low of $11.40 and a 52 week high of $72.36. The company has a market capitalization of $1.63 billion, a P/E ratio of -51.92 and a beta of 0.72.

AnaptysBio (NASDAQ:ANAB) last released its quarterly earnings data on Tuesday, May 12th. The biotechnology company reported ($1.84) EPS for the quarter, missing analysts’ consensus estimates of ($0.64) by ($1.20). AnaptysBio had a negative return on equity of 1,101.24% and a negative net margin of 11.53%.The firm had revenue of $25.56 million during the quarter, compared to analyst estimates of $18.86 million. As a group, sell-side analysts forecast that AnaptysBio will post -1.35 earnings per share for the current fiscal year.

AnaptysBio announced that its Board of Directors has initiated a share repurchase program on Friday, March 27th that authorizes the company to buyback $100,000.00 billion in shares. This buyback authorization authorizes the biotechnology company to reacquire up to 5,352,316.2% of its shares through open market purchases. Shares buyback programs are typically a sign that the company’s leadership believes its shares are undervalued.

About AnaptysBio

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.